[Atherogenic dyslipidaemia in type 2 diabetes].
This paper presents an opinion about disturbances of lipids characteristic of impaired metabolism induced by obesity and insulin resistance. In these conditions dyslipidaemia, especially with hyperglycaemia, plays a key role in the aetiopathogenesis of cardiovascular diseases. Atherogenic dyslipidaemia consists of a reduction in HDL cholesterol, elevations of triglycerides and apo B and arising of small and dense LDL and HDL particles modified by oxidation and glycation. The fundamental approach is weight reduction, increased physical activity and drug treatment leading to regression of these disturbances.
Klinika Chorób Wewnetrznych i Diabetologii, Akademia Medyczna, Poznań. zozula@box43.pl
Dorota
D
Zozulińska
D001055:Apolipoproteins B / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D008076:Cholesterol, HDL / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism*; D050171:Dyslipidemias / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism*; D006801:Humans; D006943:Hyperglycemia / Q000209:etiology / Q000378:metabolism*; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007333:Insulin Resistance; D009765:Obesity / Q000150:complications / Q000188:drug therapy / Q000378:metabolism*; D014280:Triglycerides / Q000378:metabolism
D001055:Apolipoproteins B; D008076:Cholesterol, HDL; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D014280:Triglycerides